{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:26:00Z","timestamp":1783725960403,"version":"3.55.0"},"reference-count":33,"publisher":"Japan Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1507\/endocrj.ej21-0238","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T22:07:46Z","timestamp":1627510066000},"page":"35-43","source":"Crossref","is-referenced-by-count":3,"title":["Survey of the actual administration of thiamazole for hyperthyroidism in Japan by the Japan Thyroid Association"],"prefix":"10.1507","volume":"69","author":[{"given":"Natsuko","family":"Watanabe","sequence":"first","affiliation":[{"name":"The Japan Thyroid Association, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeduk","family":"Yoshimura Noh","sequence":"additional","affiliation":[{"name":"The Japan Thyroid Association, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akamizu","sequence":"additional","affiliation":[{"name":"The Japan Thyroid Association, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Yamada","sequence":"additional","affiliation":[{"name":"The Japan Thyroid Association, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the study group members of the Japan Thyroid Association","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Burch HB, Burman KD, Cooper DS (2012) A 2011 survey of clinical practice patterns in the management of Graves\u2019 disease. J Clin Endocrinol Metab 97: 4549\u20134558.","DOI":"10.1210\/jc.2012-2802"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Brito JP, Payne S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, et al. (2020) Patterns of use, efficacy, and safety of treatment options for patients with Graves\u2019 disease: a nationwide population-based study. Thyroid 30: 357\u2013364.","DOI":"10.1089\/thy.2019.0132"},{"key":"3","unstructured":"3 The Japan Thyroid Association (ed) (2006) Guideline for the Treatment of Graves\u2019 Disease with Antithyroid Drug in Japan. Nankodo, Tokyo, Japan (In Japanese)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, et al. (2007) Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab 92: 2157\u20132162.","DOI":"10.1210\/jc.2006-2135"},{"key":"5","unstructured":"5 The Japan Thyroid Association (ed) (2011) Guideline for the Treatment of Graves\u2019 Disease in Japan. Nankodo, Tokyo, Japan (In Japanese)."},{"key":"6","unstructured":"6 The Japan Thyroid Association (ed) (2019) Guideline for the Treatment of Graves\u2019 Disease in Japan. Nankodo, Tokyo, Japan (In Japanese)."},{"key":"7","unstructured":"7 Sato H, Sasaki N, Harada S, Tanaka T, Akasu F, et al. (2008) Guidelines for the treatment of childhood-onset Graves\u2019 disease with antithyroid drug in Japan. J Jpn Pediatr Soc 112: 946\u2013952 (In Japanese)."},{"key":"8","unstructured":"8 Guidelines for the Treatment of Childhood-onset Graves\u2019 Disease with Antithyroid Drug in Japan, 2016. http:\/\/www.japanthyroid.jp\/doctor\/img\/Basedow_gl2016.pdf accessed on June 23, 2021."},{"key":"9","unstructured":"9 https:\/\/www.aska-pharma.co.jp\/iryouiyaku\/news\/filedownload.php?name=672d6470d17de70ecefd954a94d7554e.pdf accessed on June 23, 2021."},{"key":"10","unstructured":"10 http:\/\/www.japanthyroid.jp\/common\/thiamazole_chosahyo_20200312.pdf accessed on June 25, 2021."},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, et al. (2009) Methimazole-induced agranulocytosis in patients with Graves\u2019 disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19: 559\u2013563.","DOI":"10.1089\/thy.2008.0364"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12 Sato S, Noh JY, Sato S, Suzuki M, Yasuda S, et al. (2015) Comparison of efficacy and adverse effects between methimazole 15 mg<sup>+<\/sup> inorganic iodine 38 mg\/day and methimazole 30 mg\/day as initial therapy for Graves\u2019 disease patients with moderate to severe hyperthyroidism. Thyroid 25: 43\u201350.","DOI":"10.1089\/thy.2014.0084"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Takata K, Amino N, Kubota S, Sasaki I, Nishihara E, et al. (2010) Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves\u2019 disease. Clin Endocrinol (Oxf) 72: 845\u2013850.","DOI":"10.1111\/j.1365-2265.2009.03745.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Jansson R, Dahlberg PA, Johansson H, Lindstrom B (1983) Intrathyroidal concentrations of methimazole in patients with Graves\u2019 disease. J Clin Endocrinol Metab 57: 129\u2013132.","DOI":"10.1210\/jcem-57-1-129"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Roti E, Gardini E, Minelli R, Salvi M, Robuschi G, et al. (1989) Methimazole and serum thyroid hormone concentrations in hyperthyroid patients: effects of single and multiple daily doses. Ann Intern Med 111: 181\u2013182.","DOI":"10.7326\/0003-4819-111-2-181"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Nicholas WC, Fischer RG, Stevenson RA, Bass JD (1995) Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 88: 973\u2013976.","DOI":"10.1097\/00007611-199509000-00018"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Barnes HV, Bledsoe T (1972) A simple test for selecting the thioamide schedule in thyrotoxicosis. J Clin Endocrinol Metab 35: 250\u2013255.","DOI":"10.1210\/jcem-35-2-250"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Sato H, Minamitani K, Minagawa M, Kazukawa I, Sugihara S, et al. (2014) Clinical features at diagnosis and responses to antithyroid drugs in younger children with Graves\u2019 disease compared with adolescent patients. J Pediatr Endocrinol Metab 27: 677\u2013683.","DOI":"10.1515\/jpem-2013-0288"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Abuid J, Larsen PR (1974) Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents. J Clin Invest 54: 201\u2013208.","DOI":"10.1172\/JCI107744"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Isozaki O, Satoh T, Wakino S, Suzuki A, Iburi T, et al. (2016) Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol (Oxf) 84: 912\u2013918.","DOI":"10.1111\/cen.12949"},{"key":"21","unstructured":"21 The Japan Thyroid Association (ed) (2017) Guidelines for the Management of Thyroid Storm. Nankodo, Tokyo, Japan (In Japanese)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, et al. (1983) Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab 57: 563\u2013570.","DOI":"10.1210\/jcem-57-3-563"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Meng W, Meng S, Mannchen E, Hampel R, Kirsch G, et al. (1991) Effect of therapy duration and low and highly dosed thiamazole treatment in Basedow\u2019s-Graves\u2019 disease. Exp Clin Endocrinol 97: 257\u2013260.","DOI":"10.1055\/s-0029-1211074"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Jorde R, Ytre-Arne K, Stormer J, Sundsfjord J (1995) Short-term treatment of Graves\u2019 disease with methimazole in high <i>versus<\/i> low doses. J Intern Med 238: 161\u2013165.","DOI":"10.1111\/j.1365-2796.1995.tb00914.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, et al. (1997) Medical therapy of Graves\u2019 disease: does thyroxine prevent recurrence of hyperthyroidism? J Clin Endocrinol Metab 82: 2410\u20132413.","DOI":"10.1210\/jcem.82.8.4118"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Grebe SK, Feek CM, Ford HC, Fagerstrom JN, Cordwell DP, et al. (1998) A randomized trial of short-term treatment of Graves\u2019 disease with high-dose carbimazole plus thyroxine <i>versus<\/i> low-dose carbimazole. Clin Endocrinol (Oxf) 48: 585\u2013592.","DOI":"10.1046\/j.1365-2265.1998.00446.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, et al. (1998) Is there a methimazole dose effect on remission rate in Graves\u2019 disease? Results from a long-term prospective study. The European multicentre trial group of the treatment of hyperthyroidism with antithyroid drugs. Clin Endocrinol (Oxf) 49: 451\u2013457.","DOI":"10.1046\/j.1365-2265.1998.00554.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Abraham P, Avenell A, Watson WA, Park CM, Bevan JS (2004) Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev CD003420.","DOI":"10.1002\/14651858.CD003420.pub2"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS (2010) Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev 2010: CD003420.","DOI":"10.1002\/14651858.CD003420.pub4"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30 Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, et al. (2017) 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27: 315\u2013389.","DOI":"10.1089\/thy.2016.0457"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Ito S (2000) Drug therapy for breast-feeding women. N Engl J Med 343: 118\u2013126.","DOI":"10.1056\/NEJM200007133430208"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, et al. (2012) Treatment of Graves\u2019 disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 97: 2396\u20132403.","DOI":"10.1210\/jc.2011-2860"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Yoshihara A, Noh JY, Watanabe N, Mukasa K, Ohye H, et al. (2015) Substituting potassium iodide for methimazole as the treatment for Graves\u2019 disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan. Thyroid 25: 1155\u20131161.","DOI":"10.1089\/thy.2014.0581"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/69\/1\/69_EJ21-0238\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T03:22:19Z","timestamp":1643426539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/69\/1\/69_EJ21-0238\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej21-0238","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"EJ21-0238"}}